Li Jian, Wen Pu-yuan, Li Wen-wen, Zhou Jun
Departments of aClinical Immunology and Microbiology bLaboratory Medicine, Xiangya School of Medicine cDepartment of Neurology, The Third Xiangya Hospital dMedical Science Research Center, Xiangya Hospital, Central South University, Changsha, China.
Neuroreport. 2015 Sep 9;26(13):758-66. doi: 10.1097/WNR.0000000000000419.
This study aimed to observe the effects of Tanshinone IIA(Tan IIA) treatment on the expression levels of brain tissue NeuN, Nissl body, IκB, GFAP and NF-κB in Alzheimer's disease (AD) rats to explore the possible anti-inflammatory and neuroprotective mechanisms of Tan IIA. Thirty healthy male Sprague-Dawley rats were randomized into three groups: Sham group, AD+vehicle control group, and AD+Tan IIA group. The models of AD were established by injecting Aβ1-42 into the hippocampus of rats. Tagged position and the expression levels of Aβ1-42 were observed by immunohistochemistry staining to prove the success of the model of AD. Brain tissues of all groups were collected after Tan IIA treatment and paraffin sections were prepared to assess pathological changes and expression levels of GFAP, IκB and NF-κB by both immunohistochemistry and western blotting. After Aβ1-42 injection, the expression levels of GFAP and NF-κB were significantly stronger in the AD+vehicle control group than those in the AD+Tan IIA group and the sham group (P<0.05), the IκB expression level and the number of neurons and Nissl bodies of AD+vehicle control group was reduced compared with the sham or the AD+Tan IIA group (P<0.05). In conclusion, Aβ induces a cerebral tissue inflammation reaction. Tan IIA treatment can suppress the proliferation of astrocytes in an AD model, lower the level of NF-κB, and increase the level of NeuN, Nissl body, IκB, thus exerting anti-inflammatory and neuroprotective effects.
本研究旨在观察丹参酮IIA(Tan IIA)治疗对阿尔茨海默病(AD)大鼠脑组织NeuN、尼氏体、IκB、胶质纤维酸性蛋白(GFAP)和核因子κB(NF-κB)表达水平的影响,以探讨Tan IIA可能的抗炎和神经保护机制。30只健康雄性Sprague-Dawley大鼠随机分为三组:假手术组、AD+溶剂对照组和AD+Tan IIA组。通过向大鼠海马注射Aβ1-42建立AD模型。通过免疫组织化学染色观察标记位置和Aβ1-42的表达水平,以证明AD模型构建成功。Tan IIA治疗后收集所有组的脑组织并制备石蜡切片,通过免疫组织化学和蛋白质印迹法评估GFAP、IκB和NF-κB的病理变化和表达水平。注射Aβ1-42后,AD+溶剂对照组中GFAP和NF-κB的表达水平明显高于AD+Tan IIA组和假手术组(P<0.05),AD+溶剂对照组的IκB表达水平以及神经元和尼氏体数量与假手术组或AD+Tan IIA组相比降低(P<0.05)。综上所述,Aβ可诱导脑组织炎症反应。Tan IIA治疗可抑制AD模型中星形胶质细胞的增殖,降低NF-κB水平,并增加NeuN、尼氏体、IκB的水平,从而发挥抗炎和神经保护作用。